- Issue price
- ₹593per share
- Issue size
- ₹895 Cr1,50,92,749 shares
- Face value
- ₹1per equity share
- Lot size
- 25 sharesMin. ₹14,825 at the upper price
- Anchor biddingThu, 2025
- OpensFri, 2025
- ClosesTue, 2025
Information only, not investment advice. This page provides information compiled from official offer documents for information purposes only. It is not investment advice or a recommendation to apply for, buy or sell any security. We are not a SEBI-registered investment adviser or research analyst. Investments in IPOs are subject to market risks; read the offer document carefully before investing.
Issue details
- Issue type
- Book built, fresh issue and offer for sale
- Fresh issue
- 16,02,023 shares (₹95 Cr)
- Offer for sale
- 1,34,90,726 shares (₹800 Cr)
- Total issue
- 1,50,92,749 shares (₹895 Cr)
- Face value
- ₹1
- Listing at
- NSE, BSE
- Promoter holding
- 89.37% → 76.15%
Source: ProspectusUpdated
Reservation
Share of the total issue- QIB50.0%
- Retail35.0%
- NII15.0%
| Category | Shares | Of net offer | Stated in RHP |
|---|---|---|---|
| Retail individual investors | 52,82,463 | 35.00% | 35% |
| Non-institutional investors (NII) | 22,63,913 | 15.00% | 15% |
| Qualified institutional buyers (QIB) | 75,46,373 | 50.00% | 50% |
Source: ProspectusUpdated
Subscription
Category-wise subscription is published by the exchanges while the issue is open. It appears here once the figures are added.
Valuation
FY 2024-25, pre-issue- EPS (basic)
- ₹12.78
- EPS (diluted)
- ₹12.78
- P/E (FY 2024-25 at Cap Price)
- 46.40×
- RoNW
- 27.88%
- NAV per share (At Offer Price)
- ₹69.35
Source: ProspectusUpdated
Financials
Consolidated, restated · ₹ crore| Period ended | 30 Jun 20253 months | 31 Mar 2025FY 2024-25 | 31 Mar 2024FY 2023-24 | 31 Mar 2023FY 2022-23 |
|---|---|---|---|---|
| Revenue from operations | 124.92 | 502.00 | 459.28 | 428.74 |
| Total income | 130.08 | 511.33 | 465.38 | 438.26 |
| EBITDA | 49.03 | 199.28 | 187.76 | 98.64 |
| Profit after tax | 31.27 | 138.69 | 133.19 | 62.32 |
| Net worth | 688.32 | 497.53 | 359.11 | 226.29 |
| Total assets | 922.26 | 717.17 | 513.87 | 420.11 |
| Total borrowing | 135.97 | 135.25 | 75.03 | 82.26 |
FY 2024-25 vs FY 2023-24: revenue +9.3%, profit after tax +4.1%. Periods shorter than 12 months are shown as reported and are not annualised.
Source: ProspectusUpdated
About the company
The company manufactures excipients and specialty mineral-based ingredients for the pharmaceutical, food and nutrition industries. It sells to customers in India and abroad and operates manufacturing facilities in Vadodara, Gujarat, with an Irish facility added through its NSS acquisition.
- Incorporated
- 1989
- Industry
- Pharmaceutical Excipients and Specialty Ingredients
- CIN
- U24231GJ1989PLC013141
- Website
- sudeeppharma.com
Source: ProspectusUpdated
Promoters and shareholders
| Name | Before issue | After issue | Shares offered |
|---|---|---|---|
| Riva Resources Private Limited | 40.93% | 40.35% | — |
| Sujit Jaysukh Bhayani | 24.67% | 21.16% | 35,67,670 |
| Sujeet Jaysukh Bhayani HUF | 13.36% | 5.72% | 84,18,856 |
| Avani Sujit Bhayani | 5.22% | 4.47% | 7,54,200 |
| Shanil Sujit Bhayani | 5.19% | 4.45% | 7,50,000 |
| Bhayani Family Trust | 0.00% | 0.00% | — |
Source: ProspectusUpdated
Objects of the issue
₹ crore| Purpose | Amount |
|---|---|
| Procurement of machinery for the Nandesari Facility I production line | 75.81 |
| General corporate purposes | 12.67 |
Source: ProspectusUpdated
Strengths and risks
Our summary of what the offer document statesStrengths
- Long operating history since 1989 with a broad portfolio of over 100 products.
- Three Indian plants plus an Irish facility with combined capacity of 72,246 MT.
- Customer base of over 1,100 customers across multiple regions.
- Regulatory approvals including USFDA and WHO-GMP for its facilities.
- Promoters and senior management with long industry experience.
Risks
- A significant share of revenue comes from a limited number of customers.
- Most manufacturing and R&D facilities are concentrated in one region of Gujarat.
- Export sales form a large share of revenue, exposing the company to tariffs and trade changes.
- Recent acquisition of NSS may not deliver expected results.
- Selling shareholders' average acquisition cost is well below the offer price, and the company has no dividend record in recent years.
Source: ProspectusUpdated
Documents
Contacts
Source: ProspectusUpdated
Allotment status
Check whether shares were allotted on the official pages below, using your PAN, application number or DP/client ID. Results appear once the basis of allotment is finalised.
Source: ProspectusUpdated
After listing
Listing price, day-one high and low, and the change from the issue price (₹593) appear here after the shares list on NSE and BSE.
Work out the gain or loss on allotted shares after charges and tax →
Frequently asked questions
When does the Sudeep Pharma IPO open and close?
According to the Prospectus, the issue opens on Friday, 21 November 2025 and closes on Tuesday, 25 November 2025.
What is the Sudeep Pharma IPO price band?
The final issue price is ₹593 per share.
What is the lot size of the Sudeep Pharma IPO?
One lot is 25 shares, which is ₹14,825 at ₹593 per share.
Where will Sudeep Pharma shares list?
On NSE and BSE.
Who is the registrar of the issue?
MUFG Intime India Private Limited (SEBI registration INR000004058). Allotment status is checked on the registrar's website.
How do I check the Sudeep Pharma IPO allotment status?
Search by PAN, application number or DP/client ID on the registrar's website (MUFG Intime India Private Limited), the NSE website or the BSE website. Shares that are allotted are credited to your demat account; for an application that is not allotted, the blocked amount is released.
How will the money raised be used?
₹75.81 Cr for procurement of machinery for the Nandesari Facility I production line, ₹12.67 Cr for general corporate purposes.
Related IPOs
Spotted something wrong?
Our data comes from official offer documents, but mistakes can slip through. Report an error and tell us which figure looks wrong and where you saw the correct one (the offer-document page number helps). For anything else, see Contact.